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Segmental and Subcellular Distribution of CFTR
in the Kidney
François Jouret, Pierre J. Courtoy, and Olivier Devuyst
Abstract
Besides its location at the plasma membrane, CFTR is present in intracellular vesicles along both the
exocytic and the endocytic pathways. Immunostaining and subcellular fractionation studies of mouse
kidney demonstrate that CFTR is located in endosomes of the cells lining the terminal part of the prox-
imal tubule (PT). The PT cells efficiently reabsorb the ultrafiltered low molecular weight (LMW) pro-
teins by apical endocytosis involving the multiligand receptors megalin and cubilin. The progression
from early endosomes to lysosomes depends on the integrity of the cytoskeleton, as well as on vesicular
acidification. The latter is mediated by the vacuolar H+-ATPase (V-ATPase) and requires an anionic con-
ductance to dissipate the transmembrane potential gradient. CFTR might ensure such chloride conduc-
tance, thereby participating to endosomal acidification and protein uptake by PT cells. Immunostaining
with well-characterized antibodies shows that CFTR is located in the terminal segment of PT, where it
co-distributes with megalin and cubilin. Subcellular fractionation of total mouse kidneys through Per-
coll gradients demonstrates the co-localization of CFTR with the V-ATPase and early endosome mark-
ers including the Cl–/H+ exchanger, ClC-5, and the small GTPase, Rab5a. Deglycosylation studies and
immunoblotting show a distinct glycosylation pattern for CFTR in mouse kidney and lung. The segmental
and subcellular distribution of CFTR in mouse kidney supports a role for CFTR in PT receptor-mediated
endocytosis of ultrafiltered LMW proteins.
Key words: Cystic fibrosis, CFTR, ClC-5, receptor-mediated endocytosis, megalin, cubilin, endo-
somal acidification, kidney, proximal tubule cells, low molecular weight protein, antigen retrieval,
immunostaining, analytical subcellular fractionation, Percoll gradients.
1. Introduction
A significant amount of albumin and low molecular weight
(LMW) plasma proteins is continuously filtered through the
glomeruli, to be reabsorbed by proximal tubule (PT) cells (1). By
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definition, LMW proteins are characterized by a molecular mass
lower than that of albumin (69 kDa). Most filtered LMW proteins
are reabsorbed and metabolized by PT cells, and the human urine
is virtually devoid of plasma proteins under physiological condi-
tions. This massive uptake of proteins from the primitive urine
accounts for as much as 80% of the total metabolic clearance of
small proteins and peptides and plays a key role in hormone and
vitamin homeostasis (for a review, see (2)).
The uptake of LMW proteins by PT cells essentially involves
receptor-mediated endocytosis. Clathrin-mediated endocytosis
represents the predominant pathway for protein uptake across
the apical membrane of PT cells, with an endocytic pathway
consisting of five main interrelated compartments: (i) microvilli
and clathrin-coated pits, (ii) early endosomes, (iii) dense apical
tubules responsible for apical recycling, (iv) late endosomes, and
(v) lysosomes (3). The process essentially requires two multili-
gand receptors, megalin and cubilin, that are expressed at the
brush border of PT cells (2). Ligand binding and interactions
between both receptors induce their internalization into coated
vesicles and their subsequent delivery to endosomes and lyso-
somes for ligand processing and receptor degradation or recycling
(Fig. 19.1). Receptor-mediated endocytosis of albumin depends
on the integrity of the actin cytoskeleton and the microtubules
(4), whereas progression along the endocytic apparatus requires a
sustained vesicular acidification from early to late endosomes and
finally to lysosomes (5, 6). In PT cells, the endosomal acidification
is driven by the electrogenic vacuolar H+-ATPase. The translo-
cation of H+ from the cytoplasm into the endosomes generates
a transmembrane electrical potential () resulting in a rapid
inhibition of V-ATPase activity. Thus, in order to ensure progres-
sive vesicular acidification, either anions have to enter vesicles or
cations have to leave. In most cases, vesicular acidification seems
dependent on a parallel Cl− conductance (7, 8). Furthermore, the
intravesicular Cl– concentration itself could directly affect the V-
ATPase activity (9) as well as the vesicle recycling independently
of its effect on pH (6).
Besides its location at the plasma membrane, CFTR is dis-
tributed in intracellular organelles along the endocytic and secre-
tory pathways, in which it might act as a pH regulator by
importing Cl− in parallel to H+ accumulation (10). Mutant
epithelial cells derived from CF patients exhibit no cAMP-
dependent regulation of endocytosis and exocytosis, unless trans-
fected with cDNA encoding wild-type CFTR (11). Incuba-
tion of freshly isolated nasal polyps from CF patients harboring
the F508del mutation with 3-(2,4-dinitroanilino)-3′-amino-N-
methyldipropylamine (DAMP), used as a semiquantitative marker
of vesicular acidification, showed that DAMP accumulation was
significantly lowered in specific biosynthetic compartments, i.e.,










Fig. 19.1. Reabsorption of low molecular weight proteins by proximal tubule cells. Albumin and low molecular
weight (LMW) proteins that are naturally filtered by the glomerulus into the primary urine are endocytosed by PT cells
via the megalin/cubilin receptor pathway. Following internalization in coated vesicles, the receptor–ligand complexes
progress along the endocytic pathway. The endosomes undergo a progressive acidification that results in the dissociation
of the receptor–ligand complexes, with megalin and cubilin (inset) being recycled to the apical membrane, whereas the
ligand is directed to lysosomes for degradation. Modified from (18).
trans-Golgi and pre-lysosomal organelles (12). Moreover, the
monitoring of membrane potential in a light microsomal frac-
tion from CF and non-CF epithelial cells showed that acidifica-
tion is limited in CF cells by a high  resulting from insuf-
ficient Cl– counterion conductance. In turn, defective acidifica-
tion may induce lysosomal enzyme deficiencies and abnormal
trafficking and processing of newly synthesized polypeptides in
cells lacking CFTR (10). However, the role of CFTR in regulat-
ing organelle pH remains controversial, with hyper- rather than
hypo-acidification suggested to occur in CF respiratory epithelial
cells. Indeed, cell ratiometric imaging with luminally exposed pH-
sensitive green fluorescent protein has demonstrated that CFTR
decreases the pH of endosomal organelles because of a loss of
CFTR inhibitory effects on Na+ transport and a defect in cyclic
guanosine 3,5-monophosphate signaling cascade (13). In addi-
tion, recycling of transferrin receptor is impaired in CFTR mutant
lung epithelial cells, with possible functional consequences at the
plasma membrane and within endosomal compartments (14).
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This section focuses on the segmental and subcellular distri-
bution of CFTR in the epithelial cells lining the PT of mouse kid-
ney using immunostaining following antigen retrieval, as well as
immunoblotting and analytical subcellular fractionation through
Percoll gradients. These techniques defined the distribution and
role of CFTR in the endocytic pathway operating in PT cells.
Further biochemical and functional investigations performed on
CFTR-deficient mouse models and in CF patients have confirmed
the role of CFTR in the uptake of ultrafiltered LMW proteins by











1. Phosphate buffer (0.2 M, pH 7.4):
(a) Solution A: dilute 22.7 g Na2HPO4 anhydrous (Sigma
S3397, Sigma-Aldrich, St. Louis, MO) in 800 ml of
double distilled water (DDW)
(b) Solution B: dilute 6.2 g KH2PO4 (Sigma P9791) in
250 ml DDW
(c) Titrate the pH of solution A up to 7.4 by adding solu-
tion B
(d) Level it up to 1 l with DDW
2. Dilute 4 g paraformaldehyde in phosphate buffer (0.2 M,
pH 7.4)
3. Make fresh as required
4. Wear a mask when working with formaldehyde powder
2.1.2. Citrate Buffer 1. Mix in 1 l of DDW:
(a) Citric acid C6H8O7 H2O (Merck 244, Overijse, Bel-
gium): 3.77 g
(b) Sodium citrate C6H5Na3O7 2H2O (Merck
1.06448.0500): 25.12 g
2. Store the solution (1 M, pH 5.8) as aliquots at –20◦C for up
to 3 months
3. Make fresh the final solution (0.01 M), as required









1. Add 2 ml H2O2 (Sigma H1009, stable at 4◦C for up to 1
month) to 198 ml methanol
2. Make it fresh as required
2.1.5. TRIS Solution
(1 M, pH 7.4)
1. Mix in 2 l of DDW
(a) TRIZMA base (Sigma T6066): 12.2 g
(b) NaCl: 50 g
(c) HCl 32%: 8.75 ml
2. Titrate up to pH 7.4
2.1.6. TRIS-Tween
0.02%



















2.2.1. Anesthetic Drugs 1. Rompun R© (40 μg/g body weight; stock 2%; Bayer, Brus-
sels, Belgium)
2. Anesketin R© (20 μg/g body weight; Eurovet, AD Bladel,
The Netherlands)
2.2.2. SIPPI Solution 1. Sucrose (Sigma S7903) 0.25 M
2. Imidazole (Sigma I-0125) buffer 3 mM, pH 7.4
3. Protease inhibitors (Roche, Brussels, Belgium): 1 pel-
let/50 ml
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4. Phosphatase inhibitors (sodium orthovanadate 2 mM, Acros





1. Mix in 50 ml of DDW:
(a) SDS (Lauryl sulfate, Invitrogen 15525-017, Merelbeke,
Belgium): 3.75 g
(b) Glycerol (Sigma G8773): 15 ml
(c) Bromophenol blue 0.1% (Sigma B8026): 2 ml
(d) TRIS (Bio-Rad 161-0719) 1 M, pH 6.8: 2.5 ml
2. Keep at 4◦C (to avoid SDS precipitation)
2.2.5. Fairbanks Buffer
(20x)
1. Mix in 1 l of DDW
2. TRIZMA base (Sigma T6066): 48.19 g
3. Sodium acetate: 16.41 g (Sigma S3272)
4. Na-EDTA: 7.44 g (Sigma E5513)
5. Titrate to pH 7.4 with acetic acid
6. Make it fresh as required by diluting 20 times with distilled
water
2.2.6. Block Buffer 1. Mix in 800 ml of DDW
(a) Na3PO4 (Aldrich 342483) (0.5 M, pH 7.4): 80 ml
(b) NaCl 5 M: 24 ml
(c) Tween-20 (Sigma P1379): 8 ml











1. Paraffin removal: immerse the slides into xylene for 4 min.
2. Rehydration: immerse the slides for 3 min into ethanol
solutions of decreasing concentration (100–96–80–70–50–
30%). Rinse for 5 min in DDW.
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3.1.2. Antigen Retrieval
(See Note 1)
1. Immerse the slides into citrate buffer pre-warmed to 97◦C
for 75 min.
2. Let the slides in solution cool down at room temperature for
20 min.




1. Immerse the slides into methanol-H2O2 (0.3%) solution at
room temperature for 30 min.





1. Prepare the blocking solution by diluting 75 μl blocking
serum (non-immune serum of same species as primary or
secondary antibodies) into 5 ml TRIS solution. Vortex and
keep it on ice.
2. Dry the slides individually with paper and/or aspiration.
3. Delineate the tissue section with the hydrophobic pen
(5 mm far from the sample).
4. Place the slide on a support in a humid chamber.
5. Drop 150 μl blocking serum on tissue samples.




1. Dilute the primary antibodies in an Eppendorf with TRIS-
BSA 2% solution. Keep it on ice.
(a) Affinity-purified rabbit polyclonal antibodies (MD1314)
against the C-terminus of rodent CFTR (MD1314, Dr.
C.R. Marino, VA Medical Center, University of Ten-
nessee, Memphis, TN): 1/500;
(b) Rabbit polyclonal antibodies against the water channel,
AQP1 (Chemicon, Temecula, CA): 1/400.
2. Aspirate the blocking serum and drop the solution with pri-
mary antibodies on tissue samples.
3. Incubation time: 45 min.
4. Save the primary antibodies for future experiments.




1. Mix in an Eppendorf 5 ml TRIS solution, 75 μl block-
ing serum, and 25 μl secondary biotinylated antibodies
(Vector Laboratories, Brussels, Belgium; final concentration:
1/200). Vortex and keep it on ice.
2. Prepare the slides as described in Section 3.1.4.
3. Drop 150 μl of the solution with secondary antibodies on
tissue samples.
292 Jouret, Courtoy, and Devuyst
4. Incubation time: 45 min.




1. Dilute the avidin DH/biotinylated horseradish peroxi-
dase H macromolecular complex (Vectastain Elite ABC kit
PK6100, Vector Laboratories) in TRIS solution (5 ml).
2. Prepare the slides as described in Section 3.1.4.
3. Drop 150 μl of the ABC solution on tissue samples.
4. Incubation time: 45 min.






1. Immediately before use, prepare the substrate solution
according to the manufacturer’s recommendations:
(a) Add 2 drops of the Buffer Stock solution to 1 ml distilled
water;
(b) Add 3 drops of the AEC Stock solution and mix;
(c) Add 2 drops of the hydrogen peroxide solution and mix.
2. Prepare the slides as described in Section 3.1.4.
3. Drop 150 μl of the final AEC solution on tissue samples.
4. Incubation time: 15 min.
5. Rinse with distilled water (3 × 5 min).
3.1.9. Mounting of
Slides (See Note 4)
1. Aspire the liquid completely from the slide and mount them
with glycerol-enriched water.




1. Use a Leica DMR coupled to a Leica DC300 digital camera








1. Measure the mouse body weight.
2. Induce anesthesia by intraperitoneal injection of Rompun R©
(40 μg/g body weight; stock 2%; Bayer, Brussels, Bel-
gium) and Anesketin R© (20 μg/g body weight; Eurovet,
AD Bladel, The Netherlands).
3. Inject 125I-β2-microglobulin (M4890, Sigma-Aldrich) in
the periorbital plexus (typically >1,000 cpm/ng and >95%
trichloroacetic acid precipitable; ∼600 ng radioligand per
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mouse kidney
Fig. 19.2. Segmental distribution of CFTR along the mouse nephron. Immunoper-
oxidase labeling for CFTR (a) and AQP1 (b) was performed on serial sections (5 μm)
of mouse Cftr+/+ kidneys. The high signal for CFTR at the cortico-medullary junction,
combined with the segmental co-localization of CFTR and AQP1, indicates that CFTR is
particularly abundant in the apical area of the distal S3 segment of PT, just before the
transition with the descending thin limb (a and b, arrowheads). Bar: 100 μm.
gram body weight injected in a maximal volume of 150 μl;
the exact dose is calculated by weighing the syringe before
and after injection).
4. Perform laparotomy, expose kidneys and vena cava infe-
rior. Section the vein.
5. Collect a small sample of blood with a heparinized tuber-
culin syringe for further analysis.
6. Flood with PBS kept at 37◦C until no blood efflux can be
seen (∼20 s).
7. Excise exsanguinated kidneys, section the hile, and remove
kidney capsule.
8. From this point, all subsequent steps are performed at 4◦C.
9. Weigh kidneys in ice-cold SIPPI.
10. If fractionation is combined with autoradiography, ∼1/3
of one kidney is fixed by immersion in cold, 4% (w/v)
freshly prepared formaldehyde overnight, followed by rins-




1. Mince kidneys and homogenize in SIPPI with three to five
strokes of a Potter–Elvehjem tissue homogenizer (B1804,
Thomas Scientific, Swedesboro, NJ).
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2. Perform a first low-speed sedimentation at 10,000×g ×
10 min (Jouan centrifuge; 2,070 rpm, 4◦C) and collect the
first low-speed supernatant.
3. Extract again the low-speed pellet by rehomogenization
using three strokes of the Potter–Elvehjem homogenizer and
centrifuge again at 10,000×g × 10 min; the final pellet,
denoted nuclear fraction (“N”), corresponds to nuclei, cell
debris, and insoluble extracellular matrix.
4. Pool low-speed supernatants as “post-nuclear supernatant”
(referred to as “MPLS”) to a final volume of ∼8 ml; save
1 ml for further analysis.
5. Submit the remaining 7 ml to high-speed centrifugation at
100,000×g × 60 min (Ti50 rotor, Beckman, Palo Alto,
CA; 40,000 rpm), using acceleration and brake (Optima LE-
80 K ultracentrifuge, Beckman).
6. The high-speed supernatant (∼6.5 ml), denoted fraction
“S,” corresponds to the cytosol; the high-speed pellet corre-
sponds to post-nuclear particles (referred to as “MLP” frac-
tion). Resuspend this MLP fraction with a tigette in ∼2 ml
of SIPPI and further homogenize with a Dounce (loose pes-
tle). One milliliter is used for further analysis by density gra-





1. Verify that organelles are well homogenized as individual
particles by evidence of Brownian motion under phase con-
trast microscopy.
2. Mix 1 ml of post-nuclear particles with 7 ml of Percoll at 16%
(v/v) in a #355630 centrifuge tube (Beckman); the hetero-
geneity (polydispersity) of Percoll particles will ensure a self-
generating gradient upon centrifugation (in this case, close
to linearity).
3. Inject 250 μl of pure Percoll below this mixture using a
syringe equipped with a long needle, as cushion.
4. Resolve subcellular particles in this self-forming gradient by
centrifugation at 60,000×g × 30 min (30,000 rpm in the
Ti50 rotor).
5. Withdraw the brake shortly before the end of centrifugation,
when speed declines to ∼1,000 rpm.
6. Collect 10 fractions (of ∼800 μl each) in pre-weighed empty
tubes, starting by aspiration of the bottom of the tube.
7. Weigh filled tubes and determine the fraction weight by the
difference.
8. Determine density refractometry (Refractometer Abbé,
Bellingham and Stanley). The exact volume of each fraction
is given by the ratio of weight to density.

























Fig. 19.3. Immunoblotting and density distribution of CFTR in mouse kidney
homogenates using Percoll gradient. (a) Representative immunoblotting for CFTR in
lung and kidney from Cftr+/+ and Cftr–/– mice. Membrane extracts (30 μg/lane) were
run on 5% PAGE and transferred to nitrocellulose. The blot was probed with MD1314
anti-CFTR antibodies (1:500) and, after stripping, β-actin (1:10,000). In lung, both B-
(150 kDa) and C-bands (180 kDa) are present, whereas, in kidney, CFTR is detected as
a single large band at approximately 160 kDa (asterisk). In both tissues, immunoreac-
tive bands for CFTR are absent in Cftr–/– extracts. (b) Distributions after centrifugation
are presented by comparison with the initial concentration as C/Ci (broken line), where
values >1 reflect organelle enrichment and values <1 reflect organelle depletion. The
upper panel indicates the resolution of endosomal peak (Rab5a), brush border (villin),
and lysosomes (mature cathepsin D). The lower panel indicates that CFTR peaks at
the position of endosomes, is not enriched at the position of the brush border, and is
depleted at the position of lysosomes. The shape of the gradient is given by the density
as indicated below. Whereas the positions of endosomes and lysosomes are constant,
the position of the brush border varies according to slight variations of the shape of the
Percoll gradient (for additional information, see (15, 19–20)).
3.2.4. Distribution
Analysis (See Note 7)
1. Count radioactivity (e.g., Minaxi Auto Gamma 5,000 series,
Gamma counter, Packard) in dilutions corresponding to 5 μl
of injection or 10 μl of blood, in 100 μl of differential sed-
imentation fractions (nuclear fraction, post-nuclear super-
natant, post-nuclear particles, and high-speed supernatant)
and 250 μl for each fraction of the Percoll gradient.
2. Probe fractions by immunoblotting for organelle markers
(Fig. 19.3).
3.2.5. Immunoblotting 1. Handling of the samples (see Note 8)
(a) Aliquot each fraction obtained through the Percoll gra-
dient (from #1 to #10) and add sample buffer as 4/1
(v/v).
(b) Heat the samples at 60◦C for 12 min.
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(c) Place 10 μl of each sample in individual pits at the top
of 0.1 × 9 × 6 cm SDS 5%-polyacrylamide gel (PAGE)
slabs.
2. Migration of the samples through the SDS-PAGE (see Note 9)
(a) Start the migration with a potential difference of 100 V
for 10 min.
(b) Increase the potential to 200 V once the samples have
fully entered the gel. Keep it for at least 40 min.
3. Transfer of the samples from the SDS-PAGE to the nitrocellu-
lose membrane (see Note 10)
(a) Immerse the SDS-PAGE and the nitrocellulose mem-
brane between two fiber pads in Fairbanks. Cool the
solution down to 4◦C by setting ice pack in the con-
tainer.
(b) Turn it on, with a current of 250 mA for 60 min (elec-
troblotting).
(c) Remove the membrane from the SDS-PAGE and iden-
tify the molecular weight standards with a blue pen.
(d) Wash the membrane with distilled water.
4. Block of aspecific immunoreactive sites
(a) Incubate the membrane with Milk Block buffer for
30 min.
5. Incubation with primary antibodies (see Note 11)
(a) Dilute the primary antibodies in Block buffer 2% BSA:
• Affinity-purified rabbit polyclonal antibodies
(MD1314) against the C-terminus of rodent
CFTR (Dr. C.R. Marino): 1/1,500;
• Rabbit polyclonal antibodies against Rab5a (KAP-
GP006, Stressgen): 1/5000;
• Rabbit polyclonal antibodies against villin (Dr. D.
Louvard and S. Robine, Institut Curie, Paris, France):
1/10,000;
• Goat polyclonal antibodies against mature cathep-
sin D (C-20, SC6486, Santa Cruz Biotechnology):
1/2,000.
(b) Remove the Milk Block buffer.
(c) Wash the membrane with Block buffer for 5 min.
(d) Incubate the membrane overnight at 4◦C with primary
antibodies.
6. Incubation with secondary antibodies
(a) Save the primary antibodies for future experiments.
(b) Rinse with Block buffer for 15 min (2×) and 5 min
(2×).
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(c) Incubate the nitrocellulose membrane with secondary
antibodies (dilution: 1/1,500 in Milk Block) at room
temperature for 60 min.
7. Chemiluminescence detection
(a) Wash the membrane with Block buffer for 15 min (2×)
and 5 min (2×).
(b) Incubate the nitrocellulose membrane with Pierce ECL
solution (Thermo Fisher Scientific, Erembodegem, Bel-
gium).
(c) Dry the membrane and expose to X-ray film for 1–5 min
(Fig. 19.3)
4. Notes
1. Make sure that citrate buffer has been pre-warmed to 97◦C
in a water bath. Do not use a microwave oven to warm your
solutions and slides because of the lack of homogeneity in
the heating. Plunging the container filled with citrate buffer
allows a homogenous and straight heating (up to 97◦C).
2. Do not touch tissue samples during manipulations. Tissue
samples may not dry. Thus, manipulate the slides one by
one and leave the others in TRIS solution (or in the humid
chamber). Make sure that the blocking serum covers the
entire surface which has been delineated by the hydropho-
bic pen.
3. Make sure that primary antibodies have been correctly
thawed before starting the procedure. Prepare enough
solution to cover each circled area with ∼150 μl, but
retrieve precious antibodies after use. Take advantage of
each rinsing period to prepare the next solutions.
4. AEC produces a red reaction product. Slides developed
with AEC must be mounted in a water solution since the
reaction product is soluble in organic solvents. Monitor
(by eye) the incubation time, which may vary from 10 to
30 min.
5. Keep a sample from each animal in order to confirm geno-
type. For example, cut the tip of mouse tail, identify it, and
freeze it in an individual plastic bag.
6. The verification that organelles are well homogenized by
evidencing Brownian motion of individual particles under
phase contrast microscopy is essential to exclude aggrega-
tion.
7. When interpreting data, remember that (i) distributions
must be validated by recovery (sum of all fractions =
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starting material ± 20% max) and resolution (separation
between peaks) and (ii) separation is proof, co-distribution
may also reflect aggregation (16).
8. Use specific loading tip to place each sample into the
defined lane at the top of the gel. Be careful not to con-
taminate adjacent fractions when loading. One empty lane
is advised between MLP and gradient fractions.
9. Check the correct migration of the colored molecular
weight standards in order to avoid loss of target proteins
going out of the gel.
10. Check transfer efficiency by incubating the nitrocellulose
membrane with Ponceau Red dye (Sigma) for 1 min: sam-
ple smear should rapidly appear.
11. When characterizing the position of lysosomes in Percoll
gradients by probing the fractions by immunoblotting, do
not rely on LAMP-1, which is associated with both lyso-
somes and low-density endosomes. Prefer the distribution
of mature cathepsin D. Alternatively assay for N-acetyl-β-
hexosaminidase activity, which is not inhibited by protease
and phosphatase inhibitors.
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